Oura Inc. (NASDAQ: OURA) closes above $50.00 per share on its Nasdaq debut day (30 September 2026)
Pending
✦ AI-generated prediction
Published on 29. September 2026
·
Predicted for 30. September 2026
·
Based on: Speculative
Oura Inc. prices its Nasdaq IPO on the evening of 29 September 2026; first trading day is 30 September. Price range: $40–44/share (~$2.2B total offering). Order book was ~4× oversubscribed at close of bookbuilding. Strategic anchors: Eli Lilly and Dragoneer Investment Group committed ~$400M combined — pharmaceutical backing signals health-data monetisation potential. At top-of-range pricing ($44): $50 target = +13.6% first-day pop; historically achievable for 4× oversubscribed deals with strategic anchors (sector median: ~15–25% day-one return). Risk: 73% of shares are secondary (Forerunner Ventures, Lifeline Ventures cashing out), limiting net operating cash to the company and potentially creating friction with value-focused buyers. Nasdaq 100 at 30,369 (28 Sept.) — bullish backdrop.
Data basis for this prediction
- Oura IPO ~4-fach überzeichnet; Eli Lilly + Dragoneer Anchor ~400 Mio. USD (OctagonAI, Yahoo Finance, 26. Sept 2026)
- IPO Preisspanne: 40–44 USD, Ersthandelstag 30. Sept 2026 (StockAnalysis, RenaissanceCapital)
- 73 % Sekundärangebot (Forerunner/Lifeline); Vollverwässerung ~15 Mrd. USD (TechCrunch, 21. Sept 2026)
- Nasdaq 100 Schlussstand 28. Sept 2026: 30.369 Pkt. (Investing.com)
Note: This is an AI-generated statistical forecast for entertainment and information purposes. It does not constitute investment advice or a recommendation to buy or sell any financial instrument.
Verdict: Pending
This prediction is still open. It will be evaluated automatically against real-world sources after its due date.
💻 Technology
✦ AI
Anthropic has already postponed its originally targeted October 2026 Nasdaq IPO twice (most recently per TechCrunch on September 13, 2026). Prediction markets currently show 58.5% probability for completion by November 30, 2026 and 75.5% by December 31, 2026 (Polymarket, as of September 29, 2026). The company is officially IPO-ready and considered one of the year's most anticipated tech listings; Nscale also targets October 2026 and SpaceX/OpenAI eye H2 2026. Counterargument: multiple postponements and AI-regulatory complexity could push the timeline back again. Calibrated to Polymarket market quote of 58.5%.
💻 Technology
✦ AI
Chemistry World and Clarivate identify David R. Liu (Harvard University / Broad Institute) as the leading candidate for the 2026 Nobel Prize in Chemistry (announced October 8, 2026). Liu developed base editing in 2016 and prime editing in 2019 — precise genome editing methods without DNA double-strand breaks, safer and more efficient than CRISPR-Cas9. No liquid prediction market available. The 18% probability reflects the inherent unpredictability of the Nobel Committee. Alternative candidates: Shankar Balasubramanian & David Klenerman (DNA sequencing, 2026 Princess of Asturias Prize winners — historically a strong Nobel signal).
💻 Technology
✦ AI
The Kalshi market for Nobel Physics 2026 (~$8K volume, very thin) lists Kane, Kitaev, and Preskill as top candidates at ~24–30¢ each. A Physics Forums community market briefly priced E. Mele at 97% — either an insider signal or manipulation, but it illuminates sentiment. Kane & Mele described the quantum spin Hall effect in 2005, the theoretical seed of all topological quantum states; Kane received the 2023 Lorentz Medal. Serious alternative candidates: Alexei Kitaev (topological quantum computing), Qikun Xue (experimental confirmation), Aharonov/Berry (geometric phases). Honestly calibrated at 26% — the Physics prize remains structurally unpredictable.